BioRx Offers Berinert ® to Patients with Hereditary Angioedema
Cincinnati, Ohio (December 7, 2009)
BioRx, a specialty pharmacy company, has been named one of a small number of approved providers of Berinert®. Berinert® is a plasma?derived concentrate of C1 esterase
inhibitor (human) indicated for the treatment of acute abdominal or facial attacks of hereditary
angioedema (HAE) in adult and adolescent patients. CSL Behring, the manufacturer of Berinert® selected
BioRx as part of their distribution network to launch this exciting new product in the United States.
BioRx will be launching a dedicated website, www.haefreedom.com, to provide information about HAE,
treatment options, and related BioRx services.
HAE is a very rare, potentially life threatening genetic condition that causes episodes of swelling (edema)
and fluid retention in various body parts, including the hands, feet, face, and airway. Patients who have
abdominal attacks can experience episodes of severe pain, diarrhea, nausea, and vomiting caused by
swelling of the intestinal wall. Attacks that involve the face and larynx can result in airway closure,
asphyxiation, and, if untreated, death.
Diagnosis of HAE requires a blood test to confirm low or abnormal levels of C1?INH. An estimated 6,000 to
10,000 people in the United Sates have HAE.
BioRx is one of a limited number of specialty pharmacies selected by CSL Behring to dispense Berinert ®,
which was just recently approved by the US Food and Drug Administration (FDA) for the treatment of adult
and adolescent patients with acute abdominal or facial attacks of HAE. CSL Behring manufactures and sells
C1?INH concentrate in Germany, Austria, Switzerland, and several other countries under the trade name
Mark Kestler, General Manager of BioRx, says “Recognition by CSL Behring as an approved Berinert®
provider validates BioRx as a leading quality provider of specialized pharmaceutical services. We are excited
to be able to offer this valuable treatment option to HAE patients.”
Berinert® is appropriate for those who want the freedom and convenience of safe home administration of
C1?INH therapy, with approval from their physician. BioRx will provide specialized training and in? home
nursing, as well as the drug and any other supplies needed for treatment. “This new therapy for HAE
patients is consistent with similar drugs that our nurses handle every day. Highly individualized care plans
will result in our nurses either administering the drugs, or concurrently working with the families over an
extended period of time to ensure that they are comfortable and competent to manage the treatment
safely in the home,” offers Peggy Gruenemeier, RN, CRNI, BioRx’s Director of Clinical Services.
All patients who start on Berinert® receive a patient starter kit to help manage their therapy. The kit
includes helpful tools, such as administration guides, product information and a treatment journal. BioRx
employs an experienced staff of clinicians that are available 24 hours a day, 365 days a year.
More information about Berinert® at BioRx is available by calling 866?442?4679, or via email at firstname.lastname@example.org
Based in Cincinnati Ohio, BioRx is a national specialty pharmacy dedicated to providing highly customized care for
small?prevalence diseases such as Hereditary Angioedema. As one of the nation’s fastest growing providers of
biotherapeutics and blood fractions, such as Berinert?P, the company’s clinical staff reaches patients and physicians in
all 50 states. To learn more about BioRx and its products and services visit www.biorx.net.